PPAR's new course

California researchers have shown that agonizing PPARd could help stave off fibrosis in a variety of chronic liver diseases.¹ The findings could open new therapeutic areas for biotechs working on PPARd modulators, who thus far have focused on cardiovascular disease, liver disease associated with diabetes and diabetes itself.

Peroxisome proliferation-activated receptor-d (PPARD; PPARd) agonists have many beneficial properties, such as mimicking the effects of exercise, improving homeostasis of glucose and lipids, and reducing inflammation.^2,3 At least seven PPARd agonists are in clinical and preclinical development for diabetes, atherosclerosis, dyslipidemia and nonalcoholic steatohepatitis (NASH)...